Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2019-12-11T07:33:01Z | - |
dc.date.available | 2019-12-11T07:33:01Z | - |
dc.date.issued | 2019-10 | - |
dc.identifier.citation | PHARMACEUTICS, v. 11, No. 10, Article no. 540 | en_US |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://www.mdpi.com/1999-4923/11/10/540 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/121247 | - |
dc.description.abstract | Restricted drug entry to the brain that is closely associated with the existence of the blood brain barrier (BBB) has limited the accessibility of most potential active therapeutic compounds to the brain from the systemic circulation. Recently, evidences for the presence of direct nose-to-brain drug transport pathways have been accumulated by several studies and an intranasal drug administration route has gained attention as a promising way for providing direct access to the brain without the needs to cross to the BBB. Studies aiming for developing nanoparticles as an intranasal drug carrier have shown considerable promise in overcoming the challenges of intranasal drug delivery route. This review gives a comprehensive overview of works having investigated liposomes as a potential vehicle to deliver drugs to the brain through nose-to-brain route while considering the excellent biocompatibility and high potential of liposomes for clinical development. Herein, studies are reviewed with special emphasis on the impact of formulation factors, such as liposome composition and surface modification of liposomes with targeting moieties, in addition to intranasal environmental factors that may affect the extent/site of absorption of intranasally administered, liposome-encapsulated drugs. | en_US |
dc.description.sponsorship | This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2018R1A2B6003390 to S.J. Lim; 2018R1A6A3A11051339 to S.S. Hong) and a grant (16173MFDS542) from the Ministry of Food and Drug Safety in 2019. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | MDPI | en_US |
dc.subject | liposomes | en_US |
dc.subject | intranasal | en_US |
dc.subject | formulation | en_US |
dc.subject | brain delivery | en_US |
dc.subject | nanoparticle | en_US |
dc.title | Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives | en_US |
dc.type | Article | en_US |
dc.relation.no | 10 | - |
dc.relation.volume | 11 | - |
dc.identifier.doi | 10.3390/pharmaceutics11100540 | - |
dc.relation.page | 540-557 | - |
dc.relation.journal | PHARMACEUTICS | - |
dc.contributor.googleauthor | Hong, Soon-Seok | - |
dc.contributor.googleauthor | Oh, Kyung Taek | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Lim, Soo-Jeong | - |
dc.relation.code | 2019045021 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.